Zucali, P. A., Lin, C., Carthon, B. C., Bauer, T. M., Tucci, M., Italiano, A., Iacovelli, R., Su, W., Massard, C., Saleh, M., Daniele, G., Greystoke, A., Gutierrez, M., Pant, S., Shen, Y., Perrino, M., Meng, R., Abbadessa, G., Lee, H., Dong, Y., Chiron, M., Wang, R., Loumagne, L., Lépine, L., & de Bono, J. (2022). targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study. Journal for immunotherapy of cancer, 10(1), . http://access.bl.uk/ark:/81055/vdc_100150404666.0x000007